Drug Trial Radar · NCT06714123
Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Aug 1, 2025
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Vejle HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Odense Patient Data Explorative Network
- First posted
- Dec 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will investigate whether the senicapoc drug can prevent the scarring from worsening in interstitial lung disease. Researchers will compare Senicapoc to a placebo (a look-alike substance that contains no drug) to see if Senicapoc works to prevent lung function worsening. Participants will be asked to take 3 tablets a day for 26 weeks. Within this period, doctors will follow the participants, ask for experience of adverse events, check lung function and organ status, and participants will need to fill out quality-of-life questionnaires. A total of 5 visits are required, at initiation, after4, 13, 26 and 52 weeks. The final visit will occur 52 weeks after initiation and consist of a normal visit in the outpatient clinic where the doctor asks for relevant information regarding the period after end of administration of the study drug.
Conditions
- Pulmonary Fibrosis, Interstitial Lung Disease
- Idiopathic Pulmonary Fibrosis
Interventions
SenicapocDrug
administering 30 mg senicapoc a day, in addition to standard of care.
PlaceboDrug
Tablets similar in size and color
Primary outcomes
What the sponsor says the trial is designed to measure.
- The rate of decline of forced vital capacity (FVC) in mL of predicted.Time frame: 26 weeks
Locations
5 sites in 3 countries. Site status is shown where the registry gives one.
Aarhus University Hospital
Aarhus N, Denmark · Recruiting
Kardiologisk Forskningsenhed 2161, Rigshospitalet
Copenhagen, Denmark · Recruiting
Tartu University Hospital,
Tartu, Estonia · Recruiting
Division of Respiratory Sciences, Glenfield Hospital
Leicester, United Kingdom · Recruiting
University of East Anglia
Norwich, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.